CTH120 / Prous Institute for Biomedical Research, Connecta Therap - LARVOL DELTA

FIH-CTH120: CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction (clinicaltrials.gov) - P1 | N=76 | Completed | Sponsor: Connecta Therapeutics, S.L. | Recruiting ➔ Completed | Trial completion date: May 2025 ➔ Nov 2024

Trial completion • Trial completion date • Fragile X Syndrome • Genetic Disorders

FIH-CTH120: CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction (clinicaltrials.gov) - P1 | N=68 | Recruiting | Sponsor: Connecta Therapeutics, S.L. | Trial primary completion date: Jun 2024 ➔ Nov 2024

Trial primary completion date • Fragile X Syndrome • Genetic Disorders

Connecta Therapeutics Raises Funds to Advance Potential Fragile X Therapy (Fragile X News Today) - "Connecta Therapeutics raised €1.7 million (about $2 million) in investments that will enable it to bring a potential fragile X syndrome (FXS) therapy to Phase 1 clinical trials in late 2021, and to Phase 2a stage by 2023....Connecta’s potential therapy, CTH120, seeks to improve neuroplasticity....'We’re very happy that Inveready and CDTI have joined the company, not only as strategic partners and investors, but also bringing their experience in advancing projects with a huge impact on R&D....We would like to start clinical trials on this first-in-class drug as soon as possible to prove the efficacy of this therapeutic strategy” for fragile X, Fàbrega said."

Financing • New P1 trial • New P2a trial • CNS Disorders • Fragile X Syndrome